Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premixed insulin lispro twice daily versus glargine plus prandial lispro once daily for insulin intensification in type 2 diabetes
2010-019724-30Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of insulin lispro and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to week 24. Started Oct 2010; status: completed.
02
Drugs
insulin lisproinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-019724-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019724-30.